Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

It’s the first beauty brand and mascara product to receive the Arthritis Foundation’s Ease of Use certification. This means ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral therapies ...

Lorri Feldt and Eric Bechinski from the Northwest Indiana Business Development Center will give a talk to the Munster Chamber ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...